One of today's notable stocks on the rise is Celldex Therapeutics (NASDAQ:CLDX), up 1.4% to $12.00. The Dow is up 0.4% to 14,518 and the S&P is currently up 0.4% to 1,561.
In the past 52 weeks, shares of Celldex Therapeutics have traded between a low of $3.82 and a high of $12.49 and are now at $12.00, which is 214% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.9% while the 50-day MA has advanced 3.9%.
Celldex Therapeutics Inc., a biopharmaceutical company, uses applications of immunology to prevent and treat diseases. The Company's products treat autoimmune diseases, cardiovascular diseases, cancer, and inflammation, as well as infectious diseases and organ transplant rejection.
Based on a current price of $12.00, Celldex Therapeutics is currently 0.0% above its average consensus analyst price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $8.39 and subsequent support at its 200-day MA of $6.21.